文献速递基础与转化研究新药、器械与细胞基因治疗研发

Avasopasem锰通过产生过氧化氢与高分次放疗协同消融肿瘤

Avasopasem manganese synergizes with hypofractionated radiation to ablate tumors through the generation of hydrogen peroxide.
PubMed 文献 · Sci Transl Med · 2021-01-01

Avasopasem锰(AVA/GC4419)是一种选择性超氧化物歧化酶模拟物,正在头颈癌中作为放射性黏膜炎缓解剂进行3期临床试验。临床前异种移植模型显示,AVA与高分次放疗协同杀伤肿瘤,该协同作用依赖于过氧化氢的产生,并可被过氧化氢酶过表达所消除。

要点

  • AVA与高分次放疗在NSCLC、头颈鳞癌和胰腺导管腺癌模型中显示协同抗肿瘤作用。
  • 协同作用依赖于过氧化氢,肿瘤过表达过氧化氢酶可消除该效应。
  • AVA在放疗前及放疗后4天给药可进一步增强协同作用。

核心结论

  • AVA通过过氧化氢依赖机制与高分次放疗协同杀伤肿瘤,同时降低正常组织放疗损伤。

研究设计与样本

  • 临床前异种移植模型研究,使用非小细胞肺癌、头颈鳞癌和胰腺导管腺癌模型。
  • 体外使用NSCLC和乳腺腺癌模型验证机制。

主要发现

  • AVA与高分次放疗在三种肿瘤模型中显示协同作用。
  • 放疗前单次给予AVA即可产生协同,放疗前及放疗后4天给药协同进一步增强。
  • 肿瘤条件性过表达过氧化氢酶可消除协同作用。
  • AVA增加细胞内过氧化氢浓度,抑制谷胱甘肽和硫氧还蛋白依赖性过氧化氢代谢可选择性增强AVA对癌细胞的杀伤。
  • irradiated tumors treated with AVA showed increased inflammatory, TNFα, and apoptosis signaling.

临床怎么用

  • 支持AVA与类似立体定向消融放疗的高分次放疗方案联合应用的临床开发。
  • 该协同作用正在I-II期临床试验(NCT03340974)中验证。

局限性

  • 结果为临床前模型,需临床验证。
  • 协同机制依赖过氧化氢,肿瘤过氧化氢酶表达可能影响疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Avasopasem manganese (AVA or GC4419), a selective superoxide dismutase mimetic, is in a phase 3 clinical trial (NCT03689712) as a mitigator of radiation-induced mucositis in head and neck cancer based on its superoxide scavenging activity. We tested whether AVA synergized with radiation via the generation of hydrogen peroxide, the product of superoxide dismutation, to target tumor cells in preclinical xenograft models of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, and pancreatic ductal adenocarcinoma. Treatment synergy with AVA and high dose per fraction radiation occurred when mice were given AVA once before tumor irradiation and further increased when AVA was given before and for 4 days after radiation, supporting a role for oxidative metabolism. This synergy was abrogated by conditional overexpression of catalase in the tumors. In addition, in vitro NSCLC and mammary adenocarcinoma models showed that AVA increased intracellular hydrogen peroxide concentrations and buthionine sulfoximine- and auranofin-induced inhibition of glutathione- and thioredoxin-dependent hydrogen peroxide metabolism selectively enhanced AVA-induced killing of cancer cells compared to normal cells. Gene expression in irradiated tumors treated with AVA suggested that increased inflammatory, TNFα, and apoptosis signaling also contributed to treatment synergy. These results support the hypothesis that AVA, although reducing radiotherapy damage to normal tissues, acts synergistically only with high dose per fraction radiation regimens analogous to stereotactic ablative body radiotherapy against tumors by a hydrogen peroxide-dependent mechanism. This tumoricidal synergy is now being tested in a phase I-II clinical trial in humans (NCT03340974).

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Sishc BJ, Ding L, Nam TK, et al. Avasopasem manganese synergizes with hypofractionated radiation to ablate tumors through the generation of hydrogen peroxide. Sci Transl Med. 2021. PMID: 33980575. doi:10.1126/scitranslmed.abb3768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。